

ile 155:MEDLINE(R) 1951-2006/May 18
(c) format only 2006 Dialog

updated search

Set Items Description

Cost is in DialUnits

? s

Terminal set to DLINK

? s mutant? or mutation? or mutagenesis? or alter? or alteration? or deletion?
or substitutu? or addition? or insertion?

5/15/06
ef

Set	Items	Description
S1	778	CHOLERA? (25N) ADJUVANT?
S2	90	S1 AND (PORTION? OR FRAGMENT? OR MINIMAL?)
S3	45	S1 (25N) (PORTION? OR FRAGMENT? OR MINIMAL?)
S4	32	S3 AND (DOMAIN? OR SUBUNIT? OR ALPHA?)
S5	6	S2 AND MOIET?
S6	34	S4 OR S5
S7	253530	(A OR ALPHA) (5N) (DOMAIN? OR MOIET? OR FRAGMENT? OR PORTI- ON? OR SUBUNIT?)
S8	780	S7 (10N) CHOLERA?
S9	177	S8 AND (ADJUVANT? OR ENHANC?)
S10	14	S9 AND HOLOTOXIN?

? s cholera? or (ct(n)a1) or cta or ctal or holotoxin?

	223900	MUTANT?
	356134	MUTATION?
	86249	MUTAGENESIS?
	709495	ALTER?
	209703	ALTERATION?
	115810	DELETION?
	177531	SUBSTITU?
	952456	ADDITION?
	78846	INSERTION?
S11	2095629	MUTANT? OR MUTATION? OR MUTAGENESIS? OR ALTER? OR ALTERATION? OR DELETION? OR SUBSTITU? OR ADDITION? OR INSERTION?

?

	22028	CHOLERA?
	121609	CT
	21506	A1
	8	CT(N)A1
	1856	CTA
	69	CTA1
	379	HOLOTOXIN?
S12	24155	CHOLERA? OR (CT(N)A1) OR CTA OR CTA1 OR HOLOTOXIN?

?

? s s11 and s12

	2095629	S11
	24155	S12

S13 5562 S11 AND S12

? s s11 (25n) s12

	2095629	S11
	24155	S12

S14 2627 S11 (25N) S12

? s s14 and adjuvant?

	2627	S14
	86652	ADJUVANT?

S15 140 S14 AND ADJUVANT?

? s s1 and s15

	778	S1
	140	S15

S16 116 S1 AND S15
? s s16 and (alpha (5n) subunit?)
116 S16
555089 ALPHA
156562 SUBUNIT?
36490 ALPHA(5N)SUBUNIT?
S17 0 S16 AND (ALPHA (5N) SUBUNIT?)
? s16/kwic/all

16/KWIC/73

DIALOG(R)File 155:(c) format only 2006 Dialog. All rts. reserv.

We exploited the powerful **adjuvant** properties of **cholera holotoxin** (CT) to create a mucosally administered subunit vaccine against respiratory syncytial virus (RSV). A genetically detoxified **mutant** CT with an E to H **substitution** at amino acid 29 of the **CT - A1** subunit (CT-E29H) was compared to wild type CT for toxicity and potential use as an intranasal (IN) **adjuvant** for the natural fusion (F) protein of RSV. When compared to CT the results demonstrated...

... vaccinated with 0.01 microg CT-E29H or IM with F protein adsorbed to ALOH **adjuvant** . In addition, the formulation of purified F protein and CT-E29H (0.1 and 1...

... RSV challenge. Collectively, the data have important implications for vaccine strategies that use genetically detoxified **mutant cholera holotoxins** for the mucosal delivery of highly purified RSV antigens.

16/KWIC/67

DIALOG(R) File 155:(c) format only 2006 Dialog. All rts. reserv.

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.

We tested the notion that the mucosal **adjuvant cholera** toxin (CT) could target, in **addition** to nasal-associated lymphoreticular tissues, the olfactory nerves/epithelium (ON/E) and olfactory bulbs (OBs...

... monosialoganglioside (GM1) dependent. Intranasal vaccination with (125)I-tetanus toxoid together with unlabeled CT as **adjuvant** resulted in uptake into the ON/E but not the OB, whereas (125)I-tetanus...

Descriptors: ***Adjuvants** , Immunologic--administration and dosage--AD; *Axonal Transport--immunology--IM; * **Cholera** Toxin--administration and dosage--AD; * **Cholera** Vaccines--administration and dosage--AD; *Nasal Mucosa--immunology--IM; *Nasal Mucosa--innervation--IR; **Adjuvants** , Immunologic--pharmacokinetics--PK; Administration, Intranasal; Animals; Brain--immunology--IM; Brain--metabolism--ME; **Cholera** Toxin--immunology--IM; **Cholera** Toxin--pharmacokinetics--PK; **Cholera** Vaccines--immunology--IM; **Cholera** Vaccines--pharmacokinetics--PK; G(M1) Ganglioside--physiology--PH; Iodine Radioisotopes--pharmacokinetics--PK; Mice; Mice, Inbred...

Chemical Name: **Adjuvants** , Immunologic; **Cholera** Vaccines; Io

16/KWIC/66

DIALOG(R)File 155:(c) format only 2006 Dialog. All rts. reserv.

... formalin-killed bacteria and cholera toxin B subunit, protects the vaccinees (>5 years old) from **cholera** for 6 months. Vietnamese WC, a heat- and formalin-killed vaccine, is inexpensive and effective even for 1 to 5-year-old children. **Additionally**, irradiated WC vaccines and new serotype (0139) vaccines are being developed. Regarding intestinal immunity, secretory IgA has been mainly examined. In **addition**, mucosal IgG, as induced by the irradiated WC vaccine, should also be investigated. Development of mucosal **adjuvant**, such as **holotoxin**-type **mutants** of **cholera** toxin and related Escherichia coli heat-labile enterotoxin, has been actively undertaken. Diverse custom-made...

16/KWIC/39

DIALOG(R)File 155:(c) format only 2006 Dialog. All rts. reserv.

• **Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants...**
... heat-stable enterotoxin STa were fused to the N terminus of the A-subunit of cholera toxin (CTA) to explore whether peptide additions could help generate detoxified cholera toxin (CT) derivatives. Proteins carrying APRPGP (6- CTA), ASRCAELCCNPACPAP (16- CTA), or ANSSNYCCELCCNPACTGCYPGP (23- CTA) were genetically constructed. Using a two-plasmid system these derivatives were co-expressed in Vibrio...

... immune responses to a co-administered heterologous protein antigen, although in variable degrees. Therefore, the **addition** of STa-related peptides to CTA reduced the toxicity of CT while partly preserving its natural immunoadjuvanticity. These results suggest peptide extensions to CTA are a useful **alternative** to site-directed **mutagenesis** to detoxify CT. The simplicity of the procedure, combined with efficient expression and assembly of...

; Adenosine Diphosphate Ribose--metabolism--ME; **Adjuvants** , Immunologic --pharmacology--PD; Amino Acid Sequence; Animals; Blotting, Western; Catalytic Domain; Cyclic AMP--metabolism--ME...

Chemical Name: **Adjuvants** , Immunologic; DNA, Complementary; Peptides; Plasmids; Recombinant Fusion Proteins; Adenosine Diphosp

13249360 PMID: 11395467

Biological and biochemical characterization of variant A subunits of cholera toxin constructed by site-directed mutagenesis.

Jobling M G; Holmes R K

Department of Microbiology, University of Colorado Health Sciences Center, Denver, Colorado 80220, USA.

Journal of bacteriology (United States) Jul 2001, 183 (13) p4024-32, ISSN 0021-9193--Print Journal Code: 2985120R

Contract/Grant No.: AI31940; AI; NIAID

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS; Toxibib

Cholera toxin (CT) is the prototype for the *Vibrio cholerae*-*Escherichia coli* family of heat-labile enterotoxins having an AB₅ structure. By substituting amino acids in the enzymatic A subunit that are highly conserved in all members of this family, we constructed 23 variants of CT that exhibited decreased or undetectable toxicity and we characterized their biological and biochemical properties. Many variants exhibited previously undescribed temperature-sensitive assembly of **holotoxin** and/or increased sensitivity to proteolysis, which in all cases correlated with exposure of epitopes of CT-A that are normally hidden in native CT **holotoxin**. Substitutions within and deletion of the entire active-site-occluding loop demonstrated a prominent role for His-44 and this loop in the structure and activity of CT. Several novel variants with wild-type assembly and stability showed significantly decreased toxicity and enzymatic activity (e.g., variants at positions R11, I16, R25, E29, and S68+V72). In most variants the reduction in toxicity was proportional to the decrease in enzymatic activity. For substitutions or insertions at E29 and Y30 the decrease in toxicity was 10- and 5-fold more than the reduction in enzymatic activity, but for variants with R25G, E110D, or E112D substitutions the decrease in enzymatic activity was 12- to 50-fold more than the reduction in toxicity. These variants may be useful as tools for additional studies on the cell biology of toxin action and/or as attenuated toxins for **adjuvant** or vaccine use.

Descriptors: *Cholera Toxin--genetics--GE; *Cholera Toxin--toxicity--TO; **Escherichia coli* Proteins; ADP-Ribosylation Factors--genetics--GE; ADP-Ribosylation Factors--immunology--IM; ADP-Ribosylation Factors--toxicity--TO; Amino Acid Sequence; Bacterial Toxins--genetics--GE; Bacterial Toxins--toxicity--TO; Binding Sites; Cholera Toxin--immunology--IM; Comparative Study; Conserved Sequence; Enterotoxins--genetics--GE; Enterotoxins--toxicity--TO; Enzyme Stability; Epitopes; Models, Molecular; Mutagenesis, Site-Directed; Protein Conformation; Re

16/KWIC/79

DIALOG(R)File 155:(c) format only 2006 Dialog. All rts. reserv.

Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.

The effectiveness and safety of mutants of cholera toxin (CT) as an adjuvant for nasal influenza vaccine was examined. Four CT mutants, called CT7 K (Arg to Lys), CT61F (Arg to Phe), CT112 K (Glu to Lys...

... CTB IgE Ab responses were induced. The mutant CT112 K, which showed a relatively high adjuvant activity, the lowest toxicity and relatively high yields in a bacterial culture, seems to be the most effective and safest adjuvant for nasal influenza vaccine among those examined. The low dose of CT derivatives or vaccine...

... tentative plan for safety standards for human use of CT (or LT) derivatives as an adjuvant of nasal influenza vaccine is discussed.

Descriptors: *Adjuvants, Immunologic--genetics--GE; *Cholera Toxin--immunology--IM; *Influenza Vaccines--immunology--IM; *Mutation--immunology--IM; *Orthomyxoviridae Infections--prevention and control--PC; *Vaccines, Synthetic--immunology--IM; Adjuvants, Immunologic--adverse effects--AE; Administration, Intranasal; Animals; Antibodies, Viral--biosynthesis--BI; Cholera Toxin--genetics--GE; Drug Stability; Immunity, Mucosal; Immunoglobulin E--biosynthesis--BI; Influenza Vaccines--adverse effects--AE; Influenza Vaccines--genetics--GE; Mice; Mice, Inbred BALB C; Mutagenesis, Site-Directed; Vaccines, Synthetic--genetics--GE

Chemical Name: Adjuvants, Immunologic; Antibodies, Viral; Influenza Vaccines; Vaccines, Synthetic; Immunoglobulin E; Cholera Toxin

16/KWIC/90

DIALOG(R)File 155:(c) format only 2006 Dialog. All rts. reserv.

A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.

... we demonstrated that pneumococcal surface protein A (PspA) nasally administered with a nontoxic A subunit **mutant** of **cholera** toxin (mCT) S61F elicited a protective immune response. Immunization with PspA and mCT elicited higher...

... and nasal secretions. These responses were dependent on the use of mCT as a mucosal **adjuvant**. The PspA-specific Ab responses induced by mCT S61F were comparable with those induced by...

; **Adjuvants**, Immunologic--administration and dosage--AD; Administration, Intranasal; Animals; Antigens, Bacterial--administration and dosage--AD; Antigens, Bacterial--immunology--IM; Bacterial Proteins--administration and dosage--AD; Bacterial Vaccines--administration and dosage--AD; **Cholera** Toxin--administration and dosage--AD; **Cholera** Toxin--genetics--GE; Mice; Mice, Inbred C57BL; **Mutation**; Pneumococcal Infections--prevention and control--PC; Research Support, Non-U.S. Gov't; Research Support...

Chemical Name: **Adjuvants**, Immunologic; Antigens, Bacterial; Bacterial Proteins; Bacterial Vaccines; pneumococcal surface protein A; **Cholera** Toxin

WEST Search History

DATE: Monday, May 15, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L1	20040176571	1
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L2	(cholera or subunit or sub-unit) same 29	4288
<input type="checkbox"/>	L3	(cholera or subunit or sub-unit) near25 29	980
<input type="checkbox"/>	L4	l3 same alpha\$	164
<input type="checkbox"/>	L5	l4 and (vibrio or cholera)	46
<input type="checkbox"/>	L6	l1 and l2	1
<input type="checkbox"/>	L7	l1 and l3	1
<input type="checkbox"/>	L8	l1 and l4	0

END OF SEARCH HISTORY

WEST Search History

DATE: Monday, May 15, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L1	20040176571	1
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L2	(cholera or subunit or sub-unit) same 29	4288
<input type="checkbox"/>	L3	(cholera or subunit or sub-unit) near25 29	980
<input type="checkbox"/>	L4	l3 same alpha\$	164
<input type="checkbox"/>	L5	l4 and (vibrio or cholera)	46

END OF SEARCH HISTORY

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L5: Entry 2 of 46

File: PGPB

Jan 19, 2006

DOCUMENT-IDENTIFIER: US 20060014926 A1

TITLE: Human papillomavirus polypeptides and immunogenic compositions

Description of Disclosure:

[0103] Other adjuvants include mineral oil and water emulsions, aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, etc., Amphigen, Avridine, L121/squalene, D-lactide-poly(lactide)/glycoside, muramyl dipeptide, killed Bordetella, saponins, such as Quil A or Stimulon.TM. QS-21 (Antigenics, Framingham, Mass.), described in U.S. Pat. No. 5,057,540, which is hereby incorporated by reference, and particles generated therefrom such as ISCOMS (immunostimulating complexes). Mycobacterium tuberculosis, bacterial lipopolysaccharides, synthetic polynucleotides such as oligonucleotides containing a CpG motif (U.S. Pat. No. 6,207,646, which is hereby incorporated by reference), cholera toxin (either in a wild-type or mutant form, e.g., wherein the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with International Patent Publication No. WO 00/18434, incorporated herein by reference), a pertussis toxin (PI), or an E. coli heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129; see, e.g., International Patent Publication Nos. WO 93/13302 and WO 92/19265, incorporated herein by reference. Various cytokines and lymphokines are suitable for use as adjuvants. One such adjuvant is granulocyte-macrophage colony stimulating factor (GM-CSF), which has a nucleotide sequence as described in U.S. Pat. No. 5,078,996, which is hereby incorporated by reference. A plasmid containing GM-CSF cDNA has been transformed into E. coli and has been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, under Accession Number 39900. The cytokine Interleukin-12 (IL-12) is another adjuvant that is described in U.S. Pat. No. 5,723,127, which is hereby incorporated by reference. Other cytokines or lymphokines have been shown to have immune modulating activity, including, but not limited to, the interleukins 1-alpha, 1-beta, 2, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17 and 18, the interferons alpha, beta and gamma, granulocyte colony stimulating factor, and the tumor necrosis factors alpha and beta, and are suitable for use as adjuvants.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L5: Entry 5 of 46

File: PGPB

Nov 10, 2005

DOCUMENT-IDENTIFIER: US 20050249746 A1

TITLE: Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity

Summary of Invention Paragraph:

[0119] Other adjuvants include mineral oil and water emulsions, aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, etc., Amphigen, Avridine, L121/squalene, D-lactide-poly(lactide)/glycoside, pluronic polyols, muramyl dipeptide, killed Bordetella, saponins, such as Quil A or Stimulon.TM. QS-21 (Antigenics, Framingham, Mass.), described in U.S. Pat. No. 5,057,540, which is hereby incorporated by reference, and particles generated therefrom such as ISCOMS (immunostimulating complexes), Mycobacterium tuberculosis, bacterial lipopolysaccharides, synthetic polynucleotides such as oligonucleotides containing a CpG motif (U.S. Pat. No. 6,207,646, which is hereby incorporated by reference), cholera toxin (either in a wild-type or mutant form, e.g., wherein the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with International Patent Publication No. WO 00/18434, incorporated herein by reference), a pertussis toxin (PT), or an E. coli heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-SI09, PT-K9/G129; see, e.g., International Patent Publication Nos. WO 93/13302 and WO 92/19265, incorporated herein by reference. Various cytokines and lymphokines are suitable for use as adjuvants. One such adjuvant is granulocyte-macrophage colony stimulating factor (GM-CSF), which has a nucleotide sequence as described in U.S. Pat. No. 5,078,996, which is hereby incorporated by reference. A plasmid containing GM-CSF cDNA has been transformed into E. coli and has been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, under Accession Number 39900. The cytokine Interleukin-12 (IL-12) is another adjuvant that is described in U.S. Pat. No. 5,723,127, which is hereby incorporated by reference. Other cytokines or lymphokines have been shown to have immune modulating activity, including, but not limited to, the interleukins 1-alpha, 1-beta, 2, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17 and 18, the interferons-alpha, beta and gamma, granulocyte colony stimulating factor, and the tumor necrosis factors alpha and beta, and are suitable for use as adjuvants.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L5: Entry 15 of 46

File: PGPB

Jun 10, 2004

DOCUMENT-IDENTIFIER: US 20040110181 A1

TITLE: Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof

Summary of Invention Paragraph:

[0243] As defined hereinafter, an "adjuvant" is a substance that serves to enhance the immunogenicity of an "antigen" or the immunogenic compositions comprising a polypeptide antigens having an amino acid sequence chosen from one of SEQ ID NO:216 through SEQ ID NO:430 or SEQ ID NO: 592 through SEQ ID NO: 752. Thus, adjuvants are often given to boost the immune response and are well known to the skilled artisan. Examples of adjuvants contemplated in the present invention include, but are not limited to, aluminum salts (alum) such as aluminum phosphate and aluminum hydroxide, Mycobacterium tuberculosis, Bordetella pertussis, bacterial lipopolysaccharides, aminoalkyl glucosamine phosphate compounds (AGP), or derivatives or analogs thereof, which are available from Corixa (Hamilton, Mont.), and which are described in U.S. Pat. No. 6,113,918; one such AGP is 2-[(R)-3-Tetradecanoyloxytetradecanoylamino]ethyl 2-Deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyoxytetradecanoyl]-2-[(R)-3-tetradecanoyoxytetradecanoylamino]-b-D-glucopyranoside, which is also known as 529 (formerly known as RC529), which is formulated as an aqueous form or as a stable emulsion, MPL.TM. (3-O -deacylated monophosphoryl lipid A) (Corixa) described in U.S. Pat. No. 4,912,094, synthetic polynucleotides such as oligonucleotides containing a CpG motif (U.S. Pat. No. 6,207,646), polypeptides, saponins such as Quil A or STIMULON.TM. QS-21 (Antigenics, Framingham, Mass.), described in U.S. Pat. No. 5,057,540, a pertussis toxin (PT), or an E. coli heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129; see, e.g., International Patent Publication Nos. WO 93/13302 and WO 92/19265, cholera toxin (either in a wild-type or mutant form, e.g., wherein the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with published International Patent Application number WO 00/18434). Various cytokines and lymphokines are suitable for use as adjuvants. One such adjuvant is granulocyte-macrophage colony stimulating factor (GM-CSF), which has a nucleotide sequence as described in U.S. Pat. No. 5,078,996. A plasmid containing GM-CSF cDNA has been transformed into E. coli and has been deposited with the American Type Culture Collection (ATCC), 1081 University Boulevard, Manassas, Va. 20110-2209, under Accession Number 39900. The cytokine Interleukin-12(IL-12) is another adjuvant which is described in U.S. Pat. No. 5,723,127. Other cytokines or lymphokines have been shown to have immune modulating activity, including, but not limited to, the interleukins 1-alpha, 1-beta, 2, 4, 5,6, 7, 8, 10, 13, 14, 15, 16, 17 and 18, the interferons-alpha, beta and gamma, granulocyte colony stimulating factor, and the tumor necrosis factors alpha and beta, and are suitable for use as adjuvants.

Detail Description Paragraph:

[0352] Six-week old, pathogen-free, male CBA/CaHN xid/j (CBA/N) mice are purchased from Jackson Laboratories (Bar Harbor, Me.) and housed in cages under standard temperature, humidity, and lighting conditions. CBA/N mice, at 10 animals per group, are immunized with an appropriate amount of the protein(s) to be tested. For parenteral immunization, the protein is mixed with 100 .mu.g of MPL.TM. per dose to a final volume of 200 .mu.l in saline and then injected subcutaneously (SC) into mice. All groups receive a booster with the same dose and by the same route 3 and 5

weeks after the primary immunization. Control mice are injected with MPL.TM. alone. All mice are bled two weeks after the last boosting; sera is then isolated and stored at -20.degree. C. For intranasal (IN) immunization, mice receive three IN immunizations, one week apart. On each occasion, an appropriate dose of the protein to be tested is formulated with 0.1 .mu.g of CT-E29H, a genetically modified cholera toxin that is reduced in enzymatic activity and toxicity (Tebbey et al., 2000), and slowly instilled into the nostril of each mouse in a 10 .mu.l volume. Mice immunized with CT-E29H alone are used as controls. Serum samples are collected one week after the last immunization.

Detail Description Paragraph:

[0545] Tebbey et al., "Effective mucosal immunization against respiratory syncytial virus using a genetically detoxified cholera holotoxin, CT-E29H," Vaccine 18 (24):2723-34, 2000.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)